交易 Celcuity Inc - CELC 差價合約

交易條件

• 類型: 差價合約
• 點差: 0.44
• 長倉隔夜倉息調整: -0.02151%
• 短倉隔夜倉息調整: -0.00071%
• 隔夜倉息調整時間: 21:00 (UTC)
• 貨幣: USD
• 最低成交量: 1
• 保證金: 50.00%
• 證券交易所: United States of America
• 交易佣金: 0%
• 保證止損溢價: 1%

主要統計數據

• 前收盤價: 110.23
• 開倉: 106.46
• 1 年變化: -6.88%
• 日區間: 106.46 - 116.74

Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company developing companion diagnostics and targeted therapies for cancer. Its lead candidate, gedatolisib, is a dual PI3K/mTOR inhibitor for HR+/HER2- breast cancer, currently in Phase 3 development. Celcuity integrates functional cell analysis with precision oncology to identify responsive patient subgroups. The company offers high-upside exposure to targeted cancer therapeutics and biomarker-driven clinical development.